These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 25243340)

  • 1. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
    Leaker BR; Barnes PJ; Jones CR; Tutuncu A; Singh D
    Br J Clin Pharmacol; 2015 Mar; 79(3):492-500. PubMed ID: 25243340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.
    Kerwin EM; Donohue JF; Ferguson GT; Ganapathy V; Ozol-Godfrey A; Rajagopalan K
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):24-33. PubMed ID: 30457433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
    Ohar J; Tosiello R; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose selection for glycopyrrolate/eFlow
    Donohue JF; Goodin T; Tosiello R; Wheeler A
    Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
    Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
    Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
    Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
    Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study.
    Singh D; Ravi A; Reid F; Buck H; O'Connor G; Down G
    Pulm Pharmacol Ther; 2016 Apr; 37():9-14. PubMed ID: 26827913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.
    Pleasants RA
    Ann Pharmacother; 2019 Mar; 53(3):285-293. PubMed ID: 30175596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
    Mahler DA; Gifford AH; Satti A; Jessop N; Eckert JH; D'Andrea P; Mota F; Banerjee R
    Respir Med; 2016 Jun; 115():39-45. PubMed ID: 27215502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
    Reisner C; Pearle J; Kerwin EM; Rose ES; Darken P
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1965-1977. PubMed ID: 29950826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
    Rennard S; Fogarty C; Reisner C; Fernandez C; Fischer T; Golden M; Rose ES; Darken P; Tardie G; Orevillo C
    BMC Pulm Med; 2014 Jul; 14():118. PubMed ID: 25027304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
    LaForce C; Feldman G; Spangenthal S; Eckert JH; Henley M; Patalano F; D'Andrea P
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1233-43. PubMed ID: 27354782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Leaker BR; Singh D; Nicholson GC; Hezelova B; Goodin T; Ozol-Godfrey A; Galluppi G; Barnes PJ
    Respir Res; 2019 Jun; 20(1):132. PubMed ID: 31253162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of three doses of co-suspension delivery technology glycopyrronium MDI in Japanese patients with moderate-to-severe COPD.
    Fukushima Y; Nakatani Y; Ide Y; Sekino H; St Rose E; Siddiqui S; Maes A; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1187-1194. PubMed ID: 29695902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.